Literature DB >> 15270616

Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.

Guillermo A Herrera1, Lija Joseph, Xin Gu, Aubrey Hough, Bart Barlogie.   

Abstract

CONTEXT: Renal dysfunction in plasma cell dyscrasias is common. It is the second most common cause of death in patients with myeloma.
OBJECTIVE: We evaluated 77 sequential autopsies performed on patients dying from complications of plasma cell dyscrasias during an 11-year period at the University of Arkansas for Medical Sciences. These consisted of 15% of all the autopsies performed during this time.
DESIGN: The kidneys were evaluated by light microscopy using hematoxylin-eosin-stained sections as well as Congo red and thioflavin T stains when amyloidosis was in the differential diagnosis. Immunofluorescence was performed on selected cases.
RESULTS: The most common lesion identified was cast nephropathy (30%). Other findings included acute tubulopathy, AL-amyloidosis, light chain deposition disease, tubulointerstitial nephritis associated with monotypic light chain deposits, thrombotic microangiopathy, renal infarction, fungal infection, and plasma cell tumor nodules. Autolysis, an expected finding in autopsy evaluations, was significant in 25 cases.
CONCLUSIONS: Renal lesions are heterogeneous in these patients. In some cases, combined pathologic lesions were noted. Myeloma cast nephropathy predominated among all the renal lesions noted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270616     DOI: 10.5858/2004-128-875-RPSIAA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  29 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

2.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 3.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

4.  Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury.

Authors:  Wei-Zhong Ying; Xingsheng Li; Sunil Rangarajan; Wenguang Feng; Lisa M Curtis; Paul W Sanders
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

5.  Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.

Authors:  Meletios Dimopoulos; David Siegel; Darrell J White; Ralph Boccia; Karim S Iskander; Zhao Yang; Amy S Kimball; Khalid Mezzi; Heinz Ludwig; Ruben Niesvizky
Journal:  Blood       Date:  2018-11-26       Impact factor: 22.113

6.  The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.

Authors:  Richard Fish; Jennifer Pinney; Poorva Jain; Clara Addison; Chris Jones; Satish Jayawardene; John Booth; Alexander J Howie; Tareck Ghonemy; Shahista Rajabali; David Roberts; Lucy White; Sofia Khan; Matthew Morgan; Paul Cockwell; Colin A Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-22       Impact factor: 8.237

7.  Late-stage myeloma invades kidney without significant effect on renal function: findings from 53 autopsies in a single institute.

Authors:  Junichiro Takano; Sohtaro Mine; Makoto Mochizuki; Noriko Tanaka; Shotaro Hagiwara
Journal:  Int J Hematol       Date:  2018-10-16       Impact factor: 2.490

Review 8.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

9.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

Review 10.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.